Burnet Institute
The Burnet Institute is an Australian, unaligned, not-for-profit, independent organisation that links medical research with practical action to help solve devastating health problems. This sets us apart from other organisations.
| Prof Paul Dietze is one of Australia’s leading alcohol and other drug epidemiologists with a significant national, and emerging international profile. He is an NHMRC Senior Research Fellow and a past ARC Future Fellow and VicHealth Public Health Research Fellow. With more than 20 years’ experience and an outstanding track record, his work has established internationally innovative surveillance systems and applied research designs that break new ground in the public health research into alcohol and other drug use and related harms in Australia. Paul’s work has had major impact. Naloxone is now administered via the intranasal route in many parts of the USA as a result of his work in Victoria. He was a member of the ‘Guidelines Development Group on the management of opioid overdose’ for the World Health Organization, which met in Geneva in February 2014 with the guidelines released in late 2014. He has been involved in the development and implementation of a variety of heroin overdose prevention initiatives including the Direct Response to Overdose (DROP) project and he is leading the evaluation of the first Australian bystander naloxone program being implemented in the ACT. He was a key member of the Expanding Naloxone Availability in the ACT Committee. He is a Chief Investigator on a trial of intranasal naloxone in the Sydney Medically Supervised Injecting Centre that commenced in January 2012. He co-convenes the Victorian Injecting Drug Harm Reduction Network with Penington Institute through which research findings on injecting drug use are disseminated to the alcohol and drug sector. Prof Dietze currently collaborates with MARC members on various projects, including: |
| Prof Mark A Stoove is Head of Public Health at Burnet Institute where he also heads research groups in HIV Prevention and Justice Health. He has undertaken research on the epidemiology and prevention of blood borne viruses and sexually transmitted infections and the health and wellbeing of affected populations for over 20 years. His research focuses is on generating evidence for effective public health policy and practice. He has strong interests in developing novel and innovative approaches to epidemiological research to inform clinical and public health policy and practice He has led the development and maintenance of innovative sentinel surveillance systems for HIV and other sexually transmitted infections and blood borne viruses in developed and low and middle income countries. He has also led large bio-behavioural prospective cohort studies of people who inject drugs and other groups disproportionately affected by viral hepatitis, HIV and other sexually transmitted infections. I has helped lead large-scale sexual health and sexually transmitted infection prevention program implementations and randomised controlled trials in Australia and low income settings internationally. Prof Stoove currently collaborates with MARC members on various projects, including: |
| Dr Amanda Roxburgh is a Senior Research Fellow and Clinical Psychologist. Amanda has over 20 years' experience in the alcohol and other drug research sector and has a national and emerging international profile relating to her expertise in opioid overdose mortality. She has published over 50 scientific publications and delivered more than 70 national and international conference presentations. Her work is published in leading international journals. Her research has led to a greater understanding of the changing nature of opioid overdose mortality and the contribution of pharmaceutical opioids to these deaths. Amanda's work has informed legislative change in Australia (e.g. rescheduling of codeine and regulatory changes in dispensing of Schedule 8 opioids). She has led briefings to government (e.g. the Australian Government Department of Health, and the Pharmaceutical Board Advisory Committee). Written commissioned (by the Intergovernmental Committee on Drugs – IGCD and the NSW Parliament) reports which have directly informed Australia's National Drug Strategy. Her current research focuses on understanding the factors driving non-fatal and fatal overdose in the context of contemporary drug markets, with the aim of informing overdose policy responses and reducing drug-related harms. Amanda has developed strong collaborative partnerships within the sector, working with the Uniting Medically Supervised Injecting Centre in Sydney, the Medically Supervised Injecting Room in Melbourne, the Discipline of Addiction Medicine at the University of Sydney, Monash University, and the National Drug and Alcohol Research Centre, University of New South Wales. Dr Roxbourgh currently collaborates with MARC members on various projects, including: Advancing global knowledge of the drivers of fatal and non-fatal overdose |